N-acetylcysteine Attenuates Oxidative Stress and Liver Pathology in Rats with Non-alcoholic Steatohepatitis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2007 Sep 19

PMID 17876880

Citations 26

Authors

Duangporn Thong-Ngam

Suchittra Samuhasaneeto

Onanong Kulaputana

Naruemon Klaikeaw

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate attenuating properties of N-acetylcysteine (NAC) on oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis (NASH).

Methods: Male Sprague-Dawley rats were randomly divided into three groups. Group 1 (control, n=8) was free accessed to regular dry rat chow (RC) for 6 wk. Group 2 (NASH, n=8) was fed with 100% fat diet for 6 wk. Group 3 (NASH+NAC(20), n=9) was fed with 100% fat diet plus 20 mg/kg per day of NAC orally for 6 wk. All rats were sacrificed to collect blood and liver samples at the end of the study.

Results: The levels of total glutathione (GSH) and hepatic malondialdehyde (MDA) were increased significantly in the NASH group as compared with the control group (GSH; 2066.7+/-93.2 vs 1337.5+/-31.5 micromol/L and MDA; 209.9+/-43.9 vs 3.8+/-1.7 micromol/g protein, respectively, P<0.05). Liver histopathology from group 2 showed moderate to severe macrovesicular steatosis, hepatocyte ballooning, and necroinflammation. NAC treatment improved the level of GSH (1394.8+/-81.2 micromol/L, P<0.05), it did not affect MDA (150.1+/-27.0 micromol/g protein), but led to a decrease in fat deposition and necroinflammation.

Conclusion: NAC treatment could attenuate oxidative stress and improve liver histology in rats with NASH.

Citing Articles

N-acetylcysteine acts as a potent anti-inflammatory agent altering the eicosanoid profile in the development of simple steatosis and its progression to hepatitis.

Sztolsztener K, Dzieciol J, Chabowski A Clin Exp Hepatol. 2024; 9(4):386-395.

PMID: 38774197 PMC: 11103808. DOI: 10.5114/ceh.2023.133106.

Protective Role of Lycopene in Subjects with Liver Disease: NUTRIHEP Study.

Donghia R, Campanella A, Bonfiglio C, Cuccaro F, Tatoli R, Giannelli G Nutrients. 2024; 16(4).

PMID: 38398886 PMC: 10892188. DOI: 10.3390/nu16040562.

Amifostine inhibits acrylamide-induced hepatotoxicity by inhibiting oxidative stress and apoptosis.

Karimi M, Rahbardar M, Razavi B, Hosseinzadeh H Iran J Basic Med Sci. 2023; 26(6):662-668.

PMID: 37275759 PMC: 10237170. DOI: 10.22038/IJBMS.2023.67815.14837.

The Synergistic Protective Effect of γ-Oryzanol (OZ) and N-Acetylcysteine (NAC) against Experimentally Induced NAFLD in Rats Entails Hypoglycemic, Antioxidant, and PPARα Stimulatory Effects.

Alwadani A, Almasri S, Aloud A, Albadr N, Alshammari G, Yahya M Nutrients. 2023; 15(1).

PMID: 36615764 PMC: 9823776. DOI: 10.3390/nu15010106.

Changes in Glutathione Content in Liver Diseases: An Update.

Vairetti M, Di Pasqua L, Cagna M, Richelmi P, Ferrigno A, Berardo C Antioxidants (Basel). 2021; 10(3).

PMID: 33670839 PMC: 7997318. DOI: 10.3390/antiox10030364.

References

Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74. DOI: 10.1111/j.1572-0241.1999.01377.x. View

Te Sligte K, Bourass I, Sels J, Driessen A, Stockbrugger R, Koek G . Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med. 2004; 15(1):10-21. DOI: 10.1016/j.ejim.2003.12.008. View

George J, Pera N, Phung N, Leclercq I, Hou J, Farrell G . Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol. 2003; 39(5):756-64. DOI: 10.1016/s0168-8278(03)00376-3. View

Hayes J, McLellan L . Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res. 1999; 31(4):273-300. DOI: 10.1080/10715769900300851. View

Weltman M, Farrell G, Liddle C . Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996; 111(6):1645-53. DOI: 10.1016/s0016-5085(96)70028-8. View

de Knegt R . Non-alcoholic steatohepatitis: clinical significance and pathogenesis. Scand J Gastroenterol Suppl. 2002; (234):88-92. DOI: 10.1080/003655201753265505. View

Kirsch R, Clarkson V, Shephard E, Marais D, Jaffer M, Woodburne V . Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol. 2003; 18(11):1272-82. DOI: 10.1046/j.1440-1746.2003.03198.x. View

Day C . Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002; 16(5):663-78. DOI: 10.1053/bega.2002.0333. View

Koruk M, Taysi S, Savas M, Yilmaz O, Akcay F, Karakok M . Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004; 34(1):57-62. View

10.

Garcia-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez-Checa J . Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated.... Mol Pharmacol. 1995; 48(5):825-34. View

11.

Chalasani N, Deeg M, Crabb D . Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99(8):1497-502. DOI: 10.1111/j.1572-0241.2004.30159.x. View

12.

Koteish A, Diehl A . Animal models of steatosis. Semin Liver Dis. 2001; 21(1):89-104. DOI: 10.1055/s-2001-12932. View

13.

Cotgreave I . N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol. 1997; 38:205-27. View

14.

Benzie I . Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. Int J Food Sci Nutr. 1996; 47(3):233-61. DOI: 10.3109/09637489609012586. View

15.

DeFronzo R . Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med. 1997; 50(5):191-7. DOI: 10.1016/s0300-2977(97)00012-0. View

16.

Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Patumraj S, Klaikeaw N . Effects of N-acetylcysteine on oxidative stress in rats with non-alcoholic steatohepatitis. J Med Assoc Thai. 2007; 90(4):788-97. View

17.

Lieber C, Leo M, Mak K, Xu Y, Cao Q, Ren C . Model of nonalcoholic steatohepatitis. Am J Clin Nutr. 2004; 79(3):502-9. DOI: 10.1093/ajcn/79.3.502. View

18.

Fan J, Zhong L, Xu Z, Tia L, Ding X, Li M . Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol. 2003; 9(9):2045-9. PMC: 4656671. DOI: 10.3748/wjg.v9.i9.2045. View

19.

Leclercq I, Farrell G, Field J, Bell D, Gonzalez F, Robertson G . CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000; 105(8):1067-75. PMC: 300833. DOI: 10.1172/JCI8814. View

20.

Ohkawa H, Ohishi N, Yagi K . Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95(2):351-8. DOI: 10.1016/0003-2697(79)90738-3. View